Our News
RNAi Therapeutics on the European Pharmaceutical Review Podcast
August 9, 2023
Alnylam Pharmaceuticals
Paul Nioi, PhD, VP of Discovery and Translational Research and Head of Alnylam Human Genetics recently spoke with European Medical Review editor Caroline Peachey on The European Medical Review Podcast. Paul discussed the differences between and advantages of RNA interference (RNAi) versus traditional approaches to drug development, how Alnylam has overcome the challenges of delivery to different tissues, and the RNAi therapeutic drug development landscape. He and Caroline also talked about the manufacturing of RNAi therapeutics and where RNAi therapeutics fit into the broader landscape of precision medicines. To dig deeper, learn more about how genetics is driving discovery of Alnylam's next wave of RNAi therapeutics and the the science of RNAi.
Listen to the episode here.
